A lung cancer drug in everyday use, including for people with brain spread
Original title: Tarlatamab for Treatment of Small Cell Lung Cancer in Clinical Practice: A Multicenter U.S. Retrospective Cohort Study from the ONWARD consortium.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This drug is already being given to patients in regular care today.
The short version
Doctors looked back at 265 people treated with a drug called tarlatamab, and the cancer was held in check for about half of those who could be measured.
What was studied. Doctors reviewed the records of 265 patients with small cell lung cancer who got tarlatamab at 11 U.S. centers. Most had already tried other treatments. Before starting, 44.5% had new or growing cancer in the brain, and 39.2% had it in the liver.
What they found. Among the patients whose scans could be measured, the cancer stopped growing or shrank in 52.6%. Counting everyone who was treated, that number was 37.9%. After the first dose, 40.8% had a strong immune reaction, and 21.5% had brain or nerve problems such as confusion. Both became much less common with later doses. Patients given a drug called tocilizumab ahead of time had fewer immune reactions, 5.3% compared with 43.0%, and none had the brain or nerve problems compared with 22.4%.
What this means, and what it doesn't
What it could mean: This drug is already in use, and these are real patients, not a trial. It seems to help some people whose cancer has spread to the brain. The side effects are real and show up mostly with the first dose, so close watching early on matters. If this applies to you, ask your doctor whether a medicine given ahead of time could lower that risk.
What it doesn't mean: This is not a cure, and it is not a promise that the cancer will be controlled. This was a look back at old records, not a planned study, so it cannot prove what the drug caused. The side effects here were more common than in the earlier trials. The idea of giving tocilizumab ahead of time is only a hint so far and still needs a real trial. Also note this is lung cancer that spread to the brain, not a tumor that started in the brain.
Source: PubMed, November 4, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.